Frank Morich - Feb 3, 2023 Form 3 Insider Report for Isoray, Inc. (CATX)

Role
Director
Signature
/s/ Frank Morich
Stock symbol
CATX
Transactions as of
Feb 3, 2023
Transactions value $
$0
Form type
3
Date filed
2/13/2023, 03:33 PM
Previous filing
Jan 5, 2023
Next filing
Feb 23, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CATX Stock Options (right to buy) Feb 3, 2023 Common Stock 633K Direct F1, F2
holding CATX Stock Options (right to buy) Feb 3, 2023 Common Stock 475K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fully vested as of 2/3/2023 due to acceleration as a result of merger of Viewpoint Molecular Targeting, Inc. into wholly owned subsidiary of Isoray, Inc. (the "Merger").
F2 Received in exchange for options to acquire 200,000 shares of common stock in Viewpoint Molecular Targeting, Inc. at an adjusted exercise price of $0.27 per share pursuant to the terms of the Merger.
F3 Received in exchange for options to acquire 150,000 shares of common stock in Viewpoint Molecular Targeting, Inc. at an adjusted exercise price of $0.13 per share pursuant to the terms of the Merger.